7-[[2-(2-Chlorophenyl)-4-oxo-1,3-thiazolidin-3-yl]amino]-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-[[2-(2-Chlorophenyl)-4-oxo-1,3-thiazolidin-3-yl]amino]-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
• 化学式: C₂₁H₁₇ClFN₃O₄S
• 分子量: 461.9
• InChiKey: VVVHGLBVJRPXQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  115
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Prodrug antibiotic screens
  申请人：Lewis Kim

  公开号：US20080027044A1

  公开（公告）日：2008-01-31

  Methods for identifying prodrug activity utilizing screens with microbial mutants, including null and conditional mutants, transiently gene-repressed microbes, and gene-overexpressing microbes, as well as pooled collections of these are provided. Effective prodrug antibiotics differentially kill or inhibit microbes overexpressing prodrug activating genes and allow non-expressing strains to grow and be readily identified. Methods for detecting prodrug antibiotic activity by detecting a lack of differential sensitivity of multidrug efflux mutant or deficient strains are also provided. Novel pharmaceutical compounds identified by the methods of the invention, pharmaceutical formulations, and methods for treating an infection comprising administering to a subject in need thereof an effective amount of a Compound of the Invention are also provided.
• METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T CELL FUNCTION
  申请人：WANG Rongfu

  公开号：US20160030443A1

  公开（公告）日：2016-02-04

  Pharmaceutical compositions comprising a compound selected from the group consisting of Compound Nos. 1, 2, 3, 4, 5, 6, 7, 13, 22, 23, 24 and 25, as described in Table 1, and a pharmaceutically acceptable excipient. The pharmaceutical composition of the invention may further comprise an antigen, and/or an adjuvant. Also provided are methods of inhibiting a regulatory T (Treg) cell-mediated immune suppression, or more generally a method for enhancing immune response using a pharmaceutical composition comprising a ligand for human Toll-like receptor (TLR) 8 which activates the MyD88-IRAK4 signalling pathway. The present invention further provides a method of screening for an inhibitor of Treg cells' suppressive activity of host immune response using CD4 + Treg cells which express CD25, GITR and FoxP3; secrete IL-10, and are able to suppress the activation of CD4 + T cells.